From April 25 to April 30, 2025, U.S. time, ImmVira presented the Phase I clinical results of its oncolytic Herpes Simplex Virus ("oHSV") product MVR-...
Jazz Pharmaceuticals plc announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adop...
Merck, known as MSD outside of the United States and Canada, announced results from the Phase 3 KEYNOTE-689 trial evaluating KEYTRUDA® (pembrolizu...
Pfizer Inc. announced results from the pivotal Phase 3 CREST trial of sasanlimab, an investigational anti-PD-1 monoclonal antibody (mAb), in combination wi...
Cordis, a global leader in interventional cardiovascular and endovascular technologies, announced new data from two major peripheral studies evaluati...
Insmed Incorporated, a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patie...
Adcentrx Therapeutics ("Adcentrx"), a clinical-stage biotechnology company redefining Antibody-Drug Conjugate (ADC) therapies for cancer treatment and...
Boehringer Ingelheim and Tessellate Bio, a precision oncology company with a focus on developing novel synthetic lethality approaches, have entered into ...
Ascletis Pharma Inc. announces positive topline results of its randomized, double-blind, placebo-controlled Phase Ib multiple ascending d...
Bristol Myers Squibb announced topline results from the Phase 3 ARISE trial evaluating the efficacy and safety of Cobenfy (xanomeline...
Positive high-level results from a planned interim analysis of the DESTINY-Breast09 Phase III trial showed Enhertu (trastuzumab deruxtecan) in co...
Roche announced that it will invest USD 50 billion into the United States of America in the next five years. These investments further strength...
HUTCHMED (China) Limited (“HUTCHMED”) announces that it has completed enrollment of the registration phase of its Phase II trial of savol...
The Leukemia & Lymphoma Society (LLS) announced the first pediatric patient has received treatment in a new subtrial of its Pediatric Ac...
© 2025 Biopharma Boardroom. All Rights Reserved.
